Catalent Enters into Partnership with GelMEDIX to Develop iPSC-Derived Cell Therapies for Ocular and Retinal Diseases
Thursday, March 12, 2026
GelMEDIX has entered into a global partnership with Catalent to support the development and clinical manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies for ocular and retinal diseases.
Through the agreement, GelMEDIX will gain access to Catalent’s GMP-compliant iPSC lines and its expertise in cell therapy manufacturing. The collaboration aims to advance GelMEDIX’s pipeline of therapies designed to restore vision in patients with retinal and other eye-related conditions.
As part of the partnership, Catalent will support several stages of development, including process development, analytical development, process scale-up and GMP manufacturing. These services will help move GelMEDIX’s iPSC-derived therapies from early research into clinical development and through subsequent clinical stages.
The collaboration also provides GelMEDIX with access to Catalent’s proprietary off-the-shelf iPSC lines, which meet Good Manufacturing Practice (GMP) standards. Catalent’s experience in developing and manufacturing human iPSCs and iPSC-derived cells is expected to support the efficient advancement of these therapies towards clinical trials.
The partnership is intended to accelerate the development of next-generation regenerative treatments aimed at addressing serious ocular and retinal diseases and improving outcomes for patients affected by vision loss.
Source: catalent.com
